Princess Margaret Cancer Centre

Record number of Northern Ontario families seek support from Hope Air to reach medical care far from home

Retrieved on: 
Thursday, February 1, 2024

Demand for Hope Air programs for Ontario patients increases 165% in 2023 to 3,367 travel arrangements for patients in need to reach critical medical care.

Key Points: 
  • Demand for Hope Air programs for Ontario patients increases 165% in 2023 to 3,367 travel arrangements for patients in need to reach critical medical care.
  • TORONTO, Feb. 1, 2024 /CNW/ - Hope Air, Canada's national charity providing travel support to patients in financial need who must travel far from home to access vital medical care, announced an all-time annual record high in travel arrangement support for residents of Ontario.
  • Hope Air programs support the policies of government that are committed to reducing poverty and improving access to health care.
  • Over 800,000 people reside in Northern Ontario, far from advanced medical care provided by hospitals such as Sick Kids Hospital and Princess Margaret Cancer Centre.

Adela Appoints Precision Medicine Veteran Lisa Alderson as CEO

Retrieved on: 
Thursday, December 14, 2023

FOSTER CITY, Calif., Dec. 14, 2023 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, today announced the appointment of Lisa Alderson as Chief Executive Officer, following an extensive, nationwide search. Ms. Alderson is uniquely positioned to guide Adela through product scaling and commercialization, based on her prior leadership roles at Genome Medical, Invitae, and Genomic Health.

Key Points: 
  • "We are thrilled to appoint Ms. Alderson to lead Adela through its next phase of growth", said David Scheer, Chairman of Adela's Board of Directors.
  • Serving most recently as interim CEO to Adela, she has already demonstrated her ability to engage and lead this mission-driven organization in delivering results."
  • Ms. Alderson previously co-founded and served as the CEO of Genome Medical, the leading genomic care delivery company enabling broad-based access to genomic medicine.
  • "I'm excited to guide Adela through product development, commercialization and growth with the goal of applying our innovative technology to advance patient care in oncology," said Lisa Alderson, CEO, Adela.

Adela Presents Data Demonstrating Strong Prognostic Prediction Capabilities in Lung Cancer at the 2023 Multidisciplinary Thoracic Cancers Symposium

Retrieved on: 
Thursday, November 30, 2023

FOSTER CITY, Calif., Nov. 30, 2023 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome approach, is presenting data today demonstrating the feasibility of using its platform for cfDNA cancer signal quantification and prognostic prediction in early stage non-small cell lung cancer (NSCLC), during the Plenary Abstract Session at the 2023 Multidisciplinary Thoracic Cancers Symposium in New Orleans. In samples from patients with newly-diagnosed NSCLC, collected at Princess Margaret Cancer Centre at University Health Network, cancer signal from cfDNA was detected and quantified using Adela's platform, and recurrence-free survival was compared between samples with high and low cfDNA cancer signal.

Key Points: 
  • FOSTER CITY, Calif., Nov. 30, 2023 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome approach, is presenting data today demonstrating the feasibility of using its platform for cfDNA cancer signal quantification and prognostic prediction in early stage non-small cell lung cancer (NSCLC), during the Plenary Abstract Session at the 2023 Multidisciplinary Thoracic Cancers Symposium in New Orleans.
  • "Significant progress is being made in the field of oncology to develop additional adjuvant treatment options for patients with early-stage NSCLC.
  • In individuals with newly diagnosed stage I-II NSCLC, cfDNA cancer signal was quantified in 41 pre-treatment samples with a median follow-up time of 55.8 months.
  • "These data build upon Adela's existing body of evidence in Head & Neck Cancer and Renal Cell Carcinoma, demonstrating that our genome-wide methylome enrichment platform has strong prognostic prediction across multiple cancer types," said Anne-Renee Hartman, MD, Chief Medical Officer, Adela.

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
  • In the cohort of patients with gynecologic tumors, the RECIST response was 50%, OR was 60%, and CBR was 70%.
  • These patients also had a median of 3 and up to 9 prior lines of therapy, before administration of lunresertib.
  • RP-3467 is Repare’s wholly-owned Polθ inhibitor, currently in IND-enabling studies, which began in the second quarter of 2023 and remain ongoing.

Recognizing and Celebrating Outstanding Contributions to the Canadian Cancer Research Community

Retrieved on: 
Monday, November 6, 2023

TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.

Key Points: 
  • TORONTO, Nov. 6, 2023 /CNW/ - Today, the Canadian Cancer Research Alliance (CCRA) announces the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
  • Awardees will be honoured at the Canadian Cancer Research Conference, which is taking place in Halifax from November 12 to 14.
  • Initiated in 2011, the CCRA Awards acknowledge and celebrate the contributions of individuals who have had a remarkable impact on cancer research and the cancer research community, as well as those who have shown exceptional leadership in patient involvement in cancer research.
  • The Canadian Cancer Research Alliance (CCRA) is an alliance of organizations that collectively fund most of the cancer research conducted in Canada – research that will lead to better ways to prevent, diagnose, and treat cancer, and improve patient and survivor outcomes.

Adela Announces $48 Million in Financing and Leadership Addition to Advance Tissue-Agnostic Minimal Residual Disease (MRD) Monitoring Product Portfolio Based on Genome-Wide Methylome Approach

Retrieved on: 
Monday, September 25, 2023

FOSTER CITY, Calif., Sept. 25, 2023 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a genome-wide methylome approach, announced today the closing of $48 million in financing. In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr. Scott Bratman. Dr. Bratman will continue to serve as a member of Adela's Board of Directors and as President.

Key Points: 
  • In addition, the company announced that Lisa Alderson will join Adela as interim Chief Executive Officer (CEO), succeeding Dr. Scott Bratman.
  • The proceeds from the financing will be used to advance Adela's technology platform and commercialize Adela's first product for MRD monitoring.
  • Adela's tissue-agnostic MRD monitoring product is based on its genome-wide methylome enrichment platform, which efficiently captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions.
  • The proceeds will also be used to continue development of the company's multi-cancer early detection (MCED) product, based on the same platform.

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.
  • In April 2023, we received a payment of $4 million from Roche for additional revisions to the clinical development plan under the Roche Agreement.
  • The article, entitled “Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results” can be accessed here .
  • Second Quarter 2023 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of June 30, 2023 were $280.7 million, which Repare believes will be sufficient to fund its planned operations into 2026.

Melanoma is on the rise in Canada but there are ways to take action this summer

Retrieved on: 
Wednesday, June 21, 2023

Centered around education, the campaign aims to inform Canadians about some of the signs of melanoma and how to spot them.

Key Points: 
  • Centered around education, the campaign aims to inform Canadians about some of the signs of melanoma and how to spot them.
  • "The incidence of melanoma is on the rise, not only in Canada, but around the world,3" said Dr. Maxwell Sauder, onco-dermatologist at Princess Margaret Cancer Centre.
  • "It's critical that Canadians understand the seriousness of this disease and that early detection is one of our best strategies.
  • Canadians are encouraged to visit practiceskintimacy.ca where they can learn more about melanoma, connect to patient communities, and access resources to help them Practice Skintimacy™ at home.

Thousands of Canadians took to the streets of Toronto to raise $1.4 million for life-saving cancer research and clinical care at The Princess Margaret

Retrieved on: 
Sunday, June 18, 2023

This family-friendly event has raised more than $14.4 million cumulatively in support of ground-breaking cancer research, treatment, and patient care at The Princess Margaret.

Key Points: 
  • This family-friendly event has raised more than $14.4 million cumulatively in support of ground-breaking cancer research, treatment, and patient care at The Princess Margaret.
  • All routes passed by Princess Margaret Cancer Centre, with pit stops and live entertainment along the way.
  • Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world.
  • Funds raised through events like the Journey play an integral role in globally recognized research initiatives and world-leading clinical advancements.

More than 3,500 Riders Cycle Over 200km to Raise Critical Funds for Cancer Research at The Princess Margaret

Retrieved on: 
Saturday, June 10, 2023

The Princess Margaret unites Riders from across Canada and around the world for the 200km+ Ride to Conquer Cancer on June 10 and 11.

Key Points: 
  • The Princess Margaret unites Riders from across Canada and around the world for the 200km+ Ride to Conquer Cancer on June 10 and 11.
  • TORONTO, June 10, 2023 /CNW/ - More than 3,500 Riders left Exhibition Place in Toronto for The Princess Margaret Cancer Foundation's 16th annual Ride to Conquer Cancer, Canada's largest athletic fundraiser.
  • So far, this year's event has raised $17.3 million for life-saving cancer research and care at Princess Margaret Cancer Centre, one of the top 5 cancer research centres in the world.
  • "Cancer is the leading cause of death in Canada – two in five Canadians will be diagnosed with cancer in their lifetime.